Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 9, Issue 6 (November 2007) 9, 760–770; 10.1111/j.1745-7262.2007.00319.x

Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil

Tai Young Ahn, Sung Won Lee, Sae-Woong Kim, Dae Yul Yang, Nam Cheol Park, Kweon-Sik Min, Kwangsung Park, Jae-Seung Paick, Yulia Dyachkova, Trisha Dwight and Myung-Sea Luke Lee

1.Asan Medical Centre, Seoul 138-736, Korea
2.Samsung Medical Centre, Seoul 135-710, Korea
3.Youido St Marys Hospital, Seoul 150-713, Korea
4.Kang Dong Sacred Heart Hospital, Seoul 134-701, Korea
5.Pusan National University Hospital, Pusan 602-739, Korea
6.Pusan Inje University Paik Hospital, Pusan 614-735, Korea
7.Chonnam National University Hospital, Gwangju 501-757, Korea
8.Seoul National University Hospital, Seoul 110-744, Korea
9.Area Medical Centre Vienna, Eli Lilly Austria, Sydney A-1030, Australia
10.Intercontinental Information Sciences, Eli Lilly Australia, Sydney 2113, Australia
11Eli Lilly Korea, Seoul 135-280, Korea

Correspondence: Dr Trish Dwight, Intercontinental Information Sciences (ICIS), Eli Lilly Australia Pty Limited, Level 1, 16 Giffnock Avenue, Macquarie Park NSW 2113, Australia. Fax: +61-2-8874-5733. E-mail: tdwight@lilly.com

Received 22 June 2006; Accepted 11 June 2007.

Abstract

Aim: To evaluate patient preferences for sildenafil citrate or tadalafil (PDE-5 inhibitors available for the treatment of erectile dysfunction [ED]) and assess potential reasons for these preferences.

Methods: This open-label study was conducted on Korean men taking sildenafil, at least 6 weeks prior to study entry, for ED. Following screening, patients continued sildenafil treatment for 4 weeks, then after a 1-week washout period, switched to tadalafil for 8 weeks. Patients then continued with their treatment of choice during an extension phase. Psychosocial factors (time concern, spontaneity, sexual self-confidence) were evaluated using Psychological and Interpersonal Relationship Scales (PAIRS), while timing of dose to sexual attempt patterns were assessed from patient diaries.

Results: The present study enrolled 160 Korean men (mean age 55 years) with prior median sildenafil use of 585 days. During the extension phase, 73.7% of patients elected to take tadalafil, whereas 26.3% chose sildenafil (P < 0.001). After switching from sildenafil to tadalafil, mean PAIRS time concern scores decreased from 2.54 to 2.42 (P = 0.002), with no statistically significant differences observed between the sildenafil and tadalafil assessment phases in sexual spontaneity and self-confidence scores. Sexual attempts made > 4 h to 36 h post-dose occurred in 4.5% of patients during the sildenafil assessment phase compared with 17.5% during the tadalafil assessment phase.

Conclusion: After experiencing both sildenafil and tadalafil, the majority of patients exhibited a preference for tadalafil. This preference might be influenced by psychosocial factors, such as decreased time concerns, and a broader window of opportunity available for sexual activity.

Keywords: erectile dysfunction, tadalafil, sildenafil citrate, Psychological and Interpersonal Relationship Scales, preference

Full Text | PDF | 中文摘要 |

 
Browse:  3465
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.